Christine Sers is a molecular biologist and a tumor biology expert with long lasting experience in cell biological assessment of oncogene activities. She heads an experimental group consisting of PhDs and MDs and works at the interface of basic experimental and translational clinical science. She is the coordinator of several System Biology/Systems Medicine projects (Colonet, OncoPath, MapTorNet, DKTK) characterized by interdisciplinary activities including tumor biologists, pathologists, oncologists, bioinformaticians and physicists reaching for systems medicine approaches to improve patient stratification prior to treatment.
Data selection, colorectal models, screening experiments
Most Relevant Publications:
Relógio A, Thomas P, Medina-Pérez P, … , Leser U, Herzel H, Kramer A, Sers C. (2014) Ras-mediated deregulation of the circadian clock in cancer. PLoS Genet. 10(5)
Blüthgen N, Legewie S, Kielbasa SM, … , Schäfer R, Herzel H, Sers C. A systems biological approach suggests that transcriptional feedback regulation by dual-specificity phosphatase 6 shapes extracellular signal-related kinase activity in RAS-transformed fibroblasts. FEBS J. 2009 Feb;276(4):1024-35.
Jürchott, K. ,…Blüthgen, N…. Sers, C….Schäfer, R. (2010). Identification of Y-Box Binding Protein 1 as a Core Regulator of MEK/ERK Pathway-Dependent Gene Signatures in Colorectal Cancer. PLoS Genetics, 6.
Klinger, B., Sieber, A., Fritsche-Guenther, R., … Schäfer, R., Sers, C. Blüthgen, N. (2013). Network quantification of EGFR signaling unveils potential for targeted combination therapy. Molecular Systems Biology, 9.
Sers, C., Kuner, R., Falk, C. S., … , Ruschhaupt, M., Conrad, J., Mang-Fatehi, S., et al. (2009). “Downregulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells.” Int J Cancer 125(7): 1626-39.